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Giving Hope Through Research

A search for novel treatments for Parkinson’s disease, depression
and drug abuse
by Julie O’Connor

P

arkinson’s disease affects approximately one
percent of people older than 65 years of age.

Nearly one million people in the United States have
been diagnosed with Parkinson’s disease, a chronic
and progressively debilitating disorder. This motor
system disorder which causes trembling in hands,
arms, legs, jaw and face; stiffness of the limbs
and trunk; slowness of movement; and impaired
balance and coordination, is the result of the loss of
dopamine-producing brain cells.
While there is great hope in Parkinson’s disease
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research, there is no cure. A variety of medications
provide relief from the symptoms, including
levodopa, also known as L-dopa, that converts into

✼

dopamine as it reaches nerve cells in the brain.
Levodopa therapy often results in the emergence of
motor complications and eventually patients may
not respond to the drug. Multiple years of L-dopa

Dr. Aloke Dutta, professor of pharmaceutical sciences and Dr.
Prashant Khardar post-doctoral fellow, pharmaceutical sciences
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Giving Hope Through Research continued
W
treatment can cause severe side effects and possible

drug discovery and computational chemistry along

neurotoxicity leading to the withdrawal of use of

with in vitro and in vivo pharmacology, which

the drug.

ultimately will intensify development of such

But an answer to why Parkinson’s disease

agents in the near future.

develops in some patients and a cure for it remains
a mystery. “No ideal therapies are available for
slowing the progression of the degeneration process
and at the same time relieving symptomatic
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Dr. Dutta is also addressing drawbacks in current

abnormalities associated with the disease,” said

antidepressant treatments. Major depression is a

Aloke Dutta, Ph.D., professor of pharmaceutical

disorder posing significant health problems. After

sciences and medicinal chemistry in the Eugene

cardiovascular disease, depression is considered the

Applebaum College of Pharmacy and Health

second most debilitating disease in the world. “Drug

Sciences at Wayne State University.

therapies currently on the market for treatment of

Dr. Dutta aims to change this by developing a

✼

Promising new antidepressant
technology

“We believe a suitable treatment
for such a devastating addiction
will not only help people with
overcoming such addictions, but
also reduce a heavy economic
burden of our society.”

— Dr. Aloke Dutta

“One of our goals will be to study whether such

depression have many problems and shortcomings,”

novel triple uptake inhibitor molecules can produce

neuroprotective therapy that may slow down the

said Dr. Dutta. “A number of the therapies don’t

more desirable therapeutic profiles as antidepressant

degeneration process. By developing new drugs that

work for a significant number of patients, and some

agents compared to the current existing drugs

focus on relieving motor dysfunction while at the

treatments work at first, but later are ineffective.”

and whether their chronic exposure might lead

same time introducing other properties that will

According to Dr. Dutta, these treatments don’t

to the production of neurotrophic factors in the

reduce oxidative stress in the brain, Dr. Dutta hopes

address the dopamine component needed to

central nervous system via gene expression,” said

to promote survival of more dopamine neurons and

interact with the relevant targets in the brain.

Dr. Dutta. “This study has the potential to lead to

at the same time provide symptomatic relief of

Dr. Dutta and his research team along with

other possible applications, such as treatment of

the disease.

collaborators from the New York University School

obesity and neuropathic pain. This patent pending

of Medicine have discovered that by combining

technology has great promise to make a difference

Dr. Dutta and his research team have developed

three monoamine transporters blocking activities

in the lives of many,” he added.

some initial lead molecules with multifunctional

into a single molecule, a new generation of

activities which appear to exhibit some of the

antidepressants could be developed. One such

desired properties required for neuroprotection

lead polyfunctional molecule discovered in Dr.

effects along with the property to alleviate motor

Dutta’s laboratory interacts with norepinephrine,

dysfunction. Dr. Dutta and his interdisciplinary

serotonin and dopamine systems in the brain, and

research team are collaborating with researchers at

Use and Health, over 2.1 million U.S. adults

exhibited remarkable activity in preclinical in vivo

New York University School of Medicine and Baylor

reported using cocaine within 30 days prior to the

antidepressant tests, indicating that it might possess

College of Medicine. Together they are combining

survey. Currently no medication is approved for

a potent antidepressant activity.

clinics to treat this addiction.

Still early in their NIH-supported research,
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Finding a treatment for cocaine
dependency
According to the 2003 National Survey of Drug
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“The evidence from preclinical studies suggests
that the reinforcing effect of cocaine that promotes
its abuse is mostly mediated by blockade of the
presynaptic dopamine transporter resulting in
modulation of dopaminergic activity in the
mesolimbic or meso-accumbens dopamine reward
system of the brain,” said Dr. Dutta. With repeated
use, cocaine can cause long-term changes in the
brain, leading to addiction. Tolerance to the cocaine
high often develops, causing users to increase the
amount they use to intensify and prolong the
euphoria, which often leads to an increased risk of
adverse psychological or physiological effects.
Dr. Dutta’s research in the field of drug abuse
has been supported by NIH for a number of years.
“Our effort to combat cocaine addiction is directed
PAGE 25

toward rational development of small molecules
targeting the sites of interaction of cocaine in the
brain that are responsible for its strong reinforcing
effect,” said Dr. Dutta. Dr. Dutta’s research
team, which includes collaborators from New
York University School of Medicine and Virginia

“We believe a suitable treatment for such a

Commonwealth University, employs in vitro and

devastating addiction will not only help people

in vivo behavioral pharmacology and molecular

with overcoming such addictions, but also reduce a

biology studies to understand the potential of

heavy economic burden of our society,” commented

new drugs as treatment agents. His team recently

Dr. Dutta.

identified a promising lead compound, D-84, which
interacts specifically with the dopamine transporter.

About Dr. Aloke Dutta:

Currently, this compound is undergoing extensive

in Chemistry and M.S. in Organic Chemistry from Calcutta

preclinical in vivo evaluation to explore its potential

University, Calcutta, India and his Ph.D. in Organic Chemistry

to treat cocaine and methamphetamine abuse.

from Ohio University. He joined Wayne State University

Several other molecules are also being investigated.

in 1998.
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